2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2026)
San Francisco, California, US 08 January 2026 - 10 January 2026
HK study: START-FIT strategy using STRIDE regimen promising in HCC
Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (START-FIT) using the STRIDE regimen of single-dose tremelimumab plus regular-interval durvalumab offers promising efficacy and is well tolerated in patients with locally advanced, unresectable hepatocellular carcinoma (HCC), a single-arm, multicentre, phase II study in Hong Kong has shown.
HK study: START-FIT strategy using STRIDE regimen promising in HCC
17 Mar 2026
Physical activity, especially walking, relieves fatigue in CRC survivors
A study presented at ASCO GI 2026 shows that colorectal cancer (CRC) survivors who remain physically active, particularly through walking, are less likely to experience severe fatigue and more likely to report better quality of life (QoL).
Physical activity, especially walking, relieves fatigue in CRC survivors
05 Feb 2026
COMMIT: Triplet regimen extends PFS in select CRC patients
In the phase III COMMIT* trial, a combination of mFOLFOX6 (FFX), atezolizumab, and bevacizumab significantly improves progression-free survival (PFS) in patients with deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC).